Ex Parte BRUGMAN et al - Page 10




          Appeal No. 2001-1041                                      Page 10           
          Application No. 09/219,475                                                  


          Effective Dec. 1, 1997, 37 CFR § 1.109 was removed and its                  
          substance incorporated into 37 CFR § 1.104 as § 1.104(e)(1203               
          O.G. 63, 79 (Oct. 21, 1997)).  Subsequently, effective Nov. 7,              
          2000, 37 CFR § 1.104(e) was amended by deleting its last sentence           
          (underlined above), the accompanying discussion stated that this            
          statement in the rule was inconsistent with recent decisions by             
          the United States Supreme Court and the Court of Appeals for the            
          Federal Circuit2 which decisions highlight the crucial role the             
          procecution history plays in determining the validity and scope             
          of a patent (1238 O.G. 77, 103 (Sep. 19, 2000)).                            


               Appellants argue that, in not filing a statement or comments           
          in response to the examiner's reasons for allowance, they were              
          entitled to rely on the above-noted provision of the last sentence          
          of 37 CFR § 1.109/1.104(e), i.e., that failure to file such a               
          statement would not give rise to any implication that they agreed           
          with or acquiesced in the examiner's reasoning.  We agree.  It has          


               2 Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S.             
          17, 41 USPQ2d 1865 (1997); Markman v. Westview Instruments, 52              
          F.3d 967, 34 USPQ2d 1321 (Fed. Cir. 1995), aff'd, 517 U.S. 320,             
          38 USPQ2d 1461 (1996); Vitronics Corp. v. Conceptronic Inc., 90             
          F.3d 1576, 39 USPQ2d 1573 (Fed. Cir. 1996); Zenith Labs., Inc. v.           
          Bristol-Myers Squibb Co., 19 F.3d 1418, 30 USPQ2d 1285 (Fed. Cir.           
          1996).                                                                      







Page:  Previous  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  Next 

Last modified: November 3, 2007